A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors
Status:
Not yet recruiting
Trial end date:
2029-11-01
Target enrollment:
Participant gender:
Summary
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection)
given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given
intravenously Day 1 of the same 21-day cycle, for treatment of advanced solid tumors.